Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Result: Among the sequences from 782 women treated with a single dose of nevirapine, the most frequently observed mutations were K103N (28%), Y181C (15%), Y188C (6%), G190A (5%) and E138A (4%).
Result: Figure 1a shows the 16 mutations that occurred significantly more commonly in efavirenz-exposed individuals (L100I, K101P, K103N, V106I/M, V108I, V179D, Y188H/L, G190E/S/Q, P225H, F227Y, M230L and PMID: 20535242
2010
Letters in drug design & discovery
Introduction: Mutations associated with resistance to NNRTIs include L100I, K101E, K103N, V106A, V108I, V179D, Y181C, Y188C/L/H, G190A/E/S, M230L, P236L and Y318F.
Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.
Introduction: This region includes the following important and well-defined drug resistance mutations to nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs): L210W, T215Y/F and K219Q/E associated with resistance to zidovudine (AZT) and stavudine (d4T); M184I/V associated with resistance to lamivudine (3TC) and emtricitabine (FTC); and Y181C/I/V, Y188C/L/H and G190S/A associated with resistance to nevirapine (NVP), efavirenz (EFV) and etravirin (ETR).
Result: None of the five individuals had significant levels of PMID: 20668070
2010
Journal of virology
Abstract: Here, we employ stochastic simulations and a mathematical model to estimate the frequencies of strains carrying different combinations of the common nevirapine resistance mutations K103N, V106A, Y181C, Y188C, and G190A in chronically infected HIV-1 patients naive to nevirapine.
[In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors].
Abstract: NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission.
Method: NVP-R was defined by mutations present at the following amino acid sites: L100I, K101E/P, K103N/S, V106A/M, V108I, Y181C/I/V, Y188C/L/H, or G190A/S/E based on recommendations from International AIDS Society-USA Drug Resistance Mutations and Stanford University drug-resistan
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Result: NNRTI-resistant V106A and K103N variants were seen in two sequences, Y181C and Y188C in two sequences, and Y188H in five sequences.
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
PMID: 19552593
2009
AIDS research and human retroviruses
Introduction: Eight infants had mutations detected by ViroSeq [Y181C (n = 4), K103N (n = 1), V106M (n = 1), Y188C (n = 1), and V179D+K103R (n = 1)], and four infants had resistance detected by LigAmp only (all with Y181C, at 1.2%, 1.4%, 3.5%, and 7.8%; one infant also had G190A at 1.9%).
Introduction: Thirty-six (45.0%) of the 80 infants had at least one NVP resistance mutation detected; the mutations identified were Y181C (n = 28), K103N (n = 9), Y188C (n = 3), G190A (n = 30), V106A (n = 2), V106M (n
Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.
HIV mutation literature information.
PMID: 
2010
Clinical infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT